Atai Life Sciences N.V. (ATAI, Financial) experienced a significant stock drop of 5.07%, with shares priced at $1.41 and a trading volume of 597,044 shares. The turnover rate was 0.36%, and the stock's volatility reached 8.11%. Recent financial reports show revenue of $40,000 and a net loss of $26.29 million, with an EPS of -$0.16 and a gross profit of -$43,000. The P/E ratio stands at -1.78. No institutional ratings are currently available for ATAI.
Within the biotechnology sector, the overall decline was 1.13%. Notable performers include Trevi Therapeutics, Inc. and Palisade Bio, Inc., with the latter showing high trading activity and volatility.
